SEL 110

Drug Profile

SEL 110

Alternative Names: SEL-110; SVP Rapamycin; SVP-R

Latest Information Update: 26 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Selecta Biosciences
  • Class Anti-infectives; Antifungals; Antineoplastics; Gene therapies; Lactones; Macrolides; Polyenes; Pyridines
  • Mechanism of Action Immunomodulators; Methylmalonyl CoA mutase stimulants; Ornithine carbamoyltransferase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Clinical Phase Unknown Immunological disorders
  • Preclinical Methylmalonic acidaemia
  • Research Inborn urea cycle disorders

Most Recent Events

  • 15 May 2017 Preclinical trials in Methylmalonic acidaemia in USA prior to May 2017 (Parenteral)
  • 15 May 2017 Pharmacodynamic results from a preclinical trial in Methylmalonic acidaemia released by Selecta Biosciences
  • 11 May 2017 Selecta in-licenses synthetic polynucleotides encoding human methylmalonyl-CoA mutase from from the US Department of Health and Human Services
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top